| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
August 31, 2011 |
|
|
| |
|
|
| |
|
|
|
Health Network Communications, London
2011-12-06 - 2011-12-08
Covering: - How to be efficient in demonstrating safety and effectiveness in large populations
- How to collect, manage and present late phase study data in a way to demonstrate comparative
effectiveness and outcomes research - How to use enabling technologies to aid late phase research
- How to keep ahead of the game and meet the regulatory expectations for late phase research
- How to maximise the full lifecycle of a product with the use of late phase studies to identify line extensions
|
|
|
|
|
|
|
|
Organized by:
|
|
Health Network Communications |
|
|
Invited Speakers:
|
|
Representatives from - Bristol Myers Squibb
- Pfizer
- GSK
- Abbott China
- Novartis
- Boehringer-Ingelheim
- Merck Serono
- Biogen Idec
- Johnson & Johnson
- And many more!
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.healthnetworkcommunications.com/2011/late-phase-drug-development-world-europe/
|
|
|
E-mail:
|
|
sberry@healthnetworkcommunications.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|